Strongbridge Biopharma plc
SBBP · NASDAQ
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | 0.01 | -0.06 | -0.06 |
| FCF Yield | -27.98% | -38.75% | -38.11% | -17.11% |
| EV / EBITDA | -1.73 | -1.41 | 1.92 | -2.40 |
| Quality | ||||
| ROIC | -43.16% | -70.93% | -52.65% | -58.90% |
| Gross Margin | 92.80% | 82.40% | 77.89% | 78.95% |
| Cash Conversion Ratio | 0.85 | 0.91 | -2.66 | 0.40 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.46% | 45.52% | – | – |
| Free Cash Flow Growth | 14.97% | 47.16% | -87.27% | -42.95% |
| Safety | ||||
| Net Debt / EBITDA | 1.79 | 1.31 | -2.35 | 0.19 |
| Interest Coverage | -32.31 | 0.00 | -6.55 | -12.29 |
| Efficiency | ||||
| Inventory Turnover | 2.01 | 1.92 | 1.01 | 2.90 |
| Cash Conversion Cycle | -29.44 | -89.30 | 285.84 | -99.09 |